Dr. Koe worked with Albert Weissman in the 1960s, publishing two of the most seminal discoveries in the formative years of neuropharmacology. First, they developed alpha-methyl-para-tyrosine, a drug that inhibits brain catecholamine synthesis, and used it to show how amphetamine produced its psychostimulant effects by facilitating the release of catecholamines in the brain. The following year, Ken’s group introduced para-chlorophenylalanine as an inhibitor of serotonin synthesis and showed how it could be used to deplete selectively serotonin in brain. These two drugs have been used by dozens of neuropharmacology laboratories for understanding the critical role of biogenic amines in psychopharmacology and behavioral health.
Barbara Fish was the singular child psychiatrist among the founding members of the ACNP and a lead researcher of new psychotropics in children in the NIMH Early Clinical Drug Evaluation Units program. She remained a clinician researcher in a full-time academic career, treating the more severely ill children and training many of today's active child psychiatrists.
His productivity before and during his time at the National Institute of Mental Health was a springboard from which he ascended to prominence in the pharmaceutical industry and as an International leader in the fields of pharmacology, clinical pharmacology, experimental biology, and drug development. In his role as a clinical pharmacologist, he was the first to administer a number of important drugs, including Prozac (antidepressant) and pergolide (anti-parkinsonian).
Dr. Harry L. June, a Member of the College since 2004, succumbed to cancer on June 7, 2014. A native of South Carolina, Dr. June received his Ph.D. from Howard University in 1990 under Dr. Michael Lewis. Following a postdoctoral fellowship in human psychopharmacology at Johns Hopkins University, Dr. June held a dual appointment as assistant professor in the Psychology Department at Indiana University-Purdue University in Indianapolis (IUPUI) and the Medical Neurobiology Program at Indiana University School of Medicine.
Turan Itil was born in Bursa, Turkey on August 12, 1924. He received the M.D. degree from Istanbul University in 1948 and moved to the University of Tübingen in Germany for training in neurology. In 1953 he joined the faculty at the University of Erlangen with EEG and psychopharmacology the center of his research. After a decade in St. Louis, he moved to New York Medical College and established the HZI Research Center Laboratory in Tarrytown New York.
Oct 2, 2014
Dr. Daniel Hammer, 64, chief of NIAAA's section on brain electrophysiology and imaging, died on Jan. 2. He had served as head of the section since 1992, his second tenure working at NIH.
Hammer was born in Easton, Pa., and received his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine.
Andy Leon spent years training new investigators and was generous with his time and wise advice. His intellectual powers were impressive. Yet, when he helped young investigators who were struggling to design a study or interpret statistics, he would gently correct them, never criticizing or humiliating them. He would say, “Well, I have a slightly different take on that and you may want to consider approaching the problem this way”.
Ted Jones distinguished himself in many areas of neuroscience. He was unquestionably the world authority on the Thalamus, producing a remarkable two-volume book filled with his own photomicrographs and illustrations. He was a pioneer of the study of cortico-cortical circuitry and the subpopulations of neurons that comprise local cortical circuits and of neuroplasticity in the cortex and thalamus that helped define the field.
Steve Holzman was a pioneer in the use of drug discrimination procedures to investigate the pharmacological properties of opioids. His scientific publications in the 1970s-1990s contributed significantly to the widespread adoption of drug discrimination methodology to study drug-receptor interactions in behaving rodents and non-human primates; this model continues to play a key role in the preclinical development of new drugs for use in psychiatry and drug and alcohol dependence.
As the first director of an Alcoholism Service in the US Department of Veterans Affairs, Sam Kaim helped to compel armed forces personnel to recognize the significance of opioid dependence in Vietnam, leading a charge for expansion of his office in 1970 to become the Alcohol and Drug Dependence Services.
Dr. Alexander H. Glassman was a pioneer and recognized expert on the impact of psychiatric medication on the heart and the impact of depression on the development of heart disease.
John A. Harvey began his long and celebrated career as a faculty member at the University of Chicago. His research career is highlighted by many seminal scientific contributions related to the biochemistry of the brain and the development of behavioral pharmacology.
Alfred Freedman was an enthusiastic psychiatric educator and community leader willing to challenge public perceptions and prejudices. He levered the psychiatric world from its self-centered Freudian enthusiasm to caring for the less favored -- the homosexual, the addicted, women, and the imprisoned.
Wayne Fenton, M.D., is best known for his 'behind the scenes' efforts at the NIMH to transform clinical research. In 2003, recognizing the cognitive deficits in schizophrenia and the largest source of disability for many patients, Fenton led landmark NIMH efforts targeting cognitive impairments for people with schizophrenia.
The research career and contributions of Solomon C. Goldberg, Ph.D., helped forge the field of clinical
psychopharmacology clinical trials. His expertise in research methodology and statistics are reflected in the statistical techniques that he was often the first to use in clinical psychopharmacology and in the authorship of articles and chapters with biostatisticians.
Dr. Gottschalk made national headlines in the late 1980s when he concluded that President Ronald Reagan suffered from cognitive brain impairment as early as his first term, years before the late president was diagnosed with Alzheimer’s.
Jack Peter Green, M.D., Ph.D., was the founding chairperson of the Department of Pharmacology at Mount Sinai School of Medicine and led the department for almost 30 years. Dr. Green was among the first to recognize the multiple subtypes of serotonin receptors in the brain.
Gerard E. Hogarty, M.S.W., is best known for developing four psychosocial treatment approaches specific to schizophrenia.
Murray Jarvik was a founding member of ACNP. Murray was best known for his research on nicotine addiction and as a co-inventor of the nicotine patch to help people stop smoking.
In Dr. Kaufman's five years at New York University, he matured into an outstanding enzymologist and biochemist and made his first major contribution to biochemistry, the discovery of substrate phosphorylation in the conversion of a-ketoglutarate to succinate in the tricarboxylic acid cycle.
Dr. Ann E. Kelley led an eminent career in which she made
groundbreaking contributions to neuropsychopharmacology. Importantly, Dr. Kelley was a pioneer for women in science and launched the successful careers of a generation of neuroscientists through her mentoring and teaching.
Eva King Killam, Ph.D., was a founding member of the ACNP and the first female President. Her research focused on the effects and actions of drugs on the brainstem and reticular formation.
Roland Kuhn, M.D., the discoverer in 1956 of the antidepressant effect of imipramine, died October 10, 2005, at the age of 93.
Dr. Albert Kurland was the founder of
the Maryland State Psychiatric Research Center and
an eternal optimist who worked energetically and
never said an unkind word about anyone.